Tesamorelin: evidence, legality and safety
Tesamorelin is a GHRH analog FDA-approved as Egrifta to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Marketing for general body-composition or anti-aging use is off-label and not supported by approval for those purposes.
What the evidence shows
Tesamorelin is a GHRH analog FDA-approved as Egrifta to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Marketing for general body-composition or anti-aging use is off-label and not supported by approval for those purposes.
Human clinical evidence
Approval is supported by trials in the HIV-lipodystrophy indication; general-population physique claims are not established.
Animal and laboratory evidence
Preclinical GH-axis data exist. We keep animal and laboratory findings clearly separated from human evidence, because preclinical results routinely fail to translate to people.
Known and potential risks
Glucose intolerance, injection-site reactions, fluid retention; off-label use carries the added uncertainty of an unstudied population.
Legality and sourcing
The lawful pathway for any prescription peptide is a licensed clinician and a licensed pharmacy. Products labeled "for research use only" are not lawfully sold for human consumption. See how to verify a peptide provider and research peptides versus prescription therapy.
Status in sport
Prohibited under anti-doping codes.
Frequently asked questions
Is Tesamorelin FDA-approved?
FDA-approved (Egrifta) for a specific indication; other uses are off-label.
Is there human evidence for Tesamorelin?
Approval is supported by trials in the HIV-lipodystrophy indication; general-population physique claims are not established.
Is Tesamorelin legal to buy?
Many peptides in this category are sold as 'research chemicals,' which is not a lawful pathway for human use. Legitimacy depends on approval status and whether a licensed clinician and pharmacy are involved. We do not link to research-chemical sellers.
Is Tesamorelin banned in sport?
Prohibited under anti-doping codes.
Sources
- U.S. Food and Drug Administration — enforcement actions and warnings on unapproved peptide products.
- World Anti-Doping Agency (WADA) Prohibited List — current edition.
- Peer-reviewed preclinical and (where available) clinical literature, graded for evidence quality.